{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:28:11Z","timestamp":1778203691339,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["No.2016YFA0201400"],"award-info":[{"award-number":["No.2016YFA0201400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["No. 2022YFC2704204"],"award-info":[{"award-number":["No. 2022YFC2704204"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7222202"],"award-info":[{"award-number":["No. 7222202"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005089","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["No. 7222204"],"award-info":[{"award-number":["No. 7222204"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-024-01547-5","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:23:36Z","timestamp":1731587016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Near-infrared fluorescent molecular probes with cetuximab in the in vivo fluorescence imaging for epithelial ovarian cancer"],"prefix":"10.1186","volume":"17","author":[{"given":"Chen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanfen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"1547_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1547_CR2","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour Les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer. 2009;115:1234\u201344.","journal-title":"Cancer"},{"key":"1547_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1006\/gyno.1998.4955","volume":"69","author":"SM Eisenkop","year":"1998","unstructured":"Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103\u20138.","journal-title":"Gynecol Oncol"},{"key":"1547_CR4","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S1470-2045(20)30600-8","volume":"22","author":"LJ Lauwerends","year":"2021","unstructured":"Lauwerends LJ, van Driel P, Baatenburg de Jong RJ, Hardillo JAU, Koljenovic S, Puppels G, et al. Real-time fluorescence imaging in intraoperative decision making for cancer surgery. Lancet Oncol. 2021;22:e186\u201395.","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"1547_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/1471-0528.17332","volume":"129","author":"C Sun","year":"2022","unstructured":"Sun C, Huang Y, Jiang C, Li Z. Updates on fluorescent probes and open-field imaging methods for fluorescence-guided cytoreductive surgery for epithelial ovarian cancer: a review. BJOG. 2022;129(Suppl 2):50\u20139.","journal-title":"BJOG"},{"key":"1547_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","volume":"108","author":"KR Kalli","year":"2008","unstructured":"Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108:619\u201326.","journal-title":"Gynecol Oncol"},{"key":"1547_CR7","first-page":"3567","volume":"28","author":"S Markert","year":"2008","unstructured":"Markert S, Lassmann S, Gabriel B, Klar M, Werner M, Gitsch G, et al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res. 2008;28:3567\u201372.","journal-title":"Anticancer Res"},{"key":"1547_CR8","doi-asserted-by":"publisher","first-page":"e47201","DOI":"10.1371\/journal.pone.0047201","volume":"7","author":"MK Siu","year":"2012","unstructured":"Siu MK, Kong DS, Chan HY, Wong ES, Ip PP, Jiang L, et al. Paradoxical impact of two folate receptors, FRalpha and RFC, in ovarian cancer: effect on cell proliferation, invasion and clinical outcome. PLoS ONE. 2012;7:e47201.","journal-title":"PLoS ONE"},{"key":"1547_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F","volume":"74","author":"G Toffoli","year":"1997","unstructured":"Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997;74:193\u20138.","journal-title":"Int J Cancer"},{"key":"1547_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ygyno.2019.07.010","volume":"155","author":"LM Randall","year":"2019","unstructured":"Randall LM, Wenham RM, Low PS, Dowdy SC, Tanyi JL. A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer. Gynecol Oncol. 2019;155:63\u20138.","journal-title":"Gynecol Oncol"},{"key":"1547_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.22.00291","volume":"41","author":"JL Tanyi","year":"2023","unstructured":"Tanyi JL, Randall LM, Chambers SK, Butler KA, Winer IS, Langstraat CL, et al. A phase III study of pafolacianine injection (OTL38) for intraoperative imaging of Folate receptor-positive ovarian Cancer (study 006). J Clin Oncol. 2023;41:276\u201384.","journal-title":"J Clin Oncol"},{"key":"1547_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.4155\/fmc.12.11","volume":"4","author":"JA Wilken","year":"2012","unstructured":"Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, et al. EGFR\/HER-targeted therapeutics in ovarian cancer. Future Med Chem. 2012;4:447\u201369.","journal-title":"Future Med Chem"},{"key":"1547_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/jnci\/93.18.1375","volume":"93","author":"O Alper","year":"2001","unstructured":"Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst. 2001;93:1375\u201384.","journal-title":"J Natl Cancer Inst"},{"key":"1547_CR14","first-page":"232","volume":"1785","author":"JM Lafky","year":"2008","unstructured":"Lafky JM, Wilken JA, Baron AT, Maihle NJ. Clinical implications of the ErbB\/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 2008;1785:232\u201365.","journal-title":"Biochim Biophys Acta"},{"key":"1547_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13046-023-02651-y","volume":"42","author":"L Forlani","year":"2023","unstructured":"Forlani L, De Cecco L, Simeon V, Paolini B, Bagnoli M, Cecere SC, et al. Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A\/MANGO-OV2A trial. J Exp Clin Cancer Res. 2023;42:83.","journal-title":"J Exp Clin Cancer Res"},{"key":"1547_CR16","first-page":"370","volume":"24","author":"A Poursheikhani","year":"2020","unstructured":"Poursheikhani A, Yousefi H, Tavakoli-Bazzaz J, Seyed HG. EGFR Blockade reverses Cisplatin Resistance in Human epithelial ovarian Cancer cells. Iran Biomed J. 2020;24:370\u20138.","journal-title":"Iran Biomed J"},{"key":"1547_CR17","doi-asserted-by":"publisher","first-page":"114536","DOI":"10.1016\/j.bcp.2021.114536","volume":"190","author":"J Zhao","year":"2021","unstructured":"Zhao J, Tan W, Zhang L, Liu J, Shangguan M, Chen J, et al. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer. Biochem Pharmacol. 2021;190:114536.","journal-title":"Biochem Pharmacol"},{"key":"1547_CR18","first-page":"2287","volume":"19","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Tao L, Fan LX, Huang K, Luo HM, Ge H, et al. Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR\u2013Akt pathway. Mol Med Rep. 2019;19:2287\u201396.","journal-title":"Mol Med Rep"},{"key":"1547_CR19","doi-asserted-by":"publisher","first-page":"6361","DOI":"10.1002\/jcp.27369","volume":"234","author":"M Zhang","year":"2019","unstructured":"Zhang M, Cong Q, Zhang XY, Zhang MX, Lu YY, Xu CJ. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation. J Cell Physiol. 2019;234:6361\u201370.","journal-title":"J Cell Physiol"},{"key":"1547_CR20","first-page":"1601","volume":"8","author":"D Li","year":"2016","unstructured":"Li D, Wu QJ, Bi FF, Chen SL, Zhou YM, Zhao Y, et al. Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer. Am J Transl Res. 2016;8:1601\u20138.","journal-title":"Am J Transl Res"},{"key":"1547_CR21","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/onc.2011.409","volume":"31","author":"P Yue","year":"2012","unstructured":"Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway RW, et al. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene. 2012;31:2309\u201322.","journal-title":"Oncogene"},{"key":"1547_CR22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.21147\/j.issn.1000-9604.2019.04.11","volume":"31","author":"C Zhang","year":"2019","unstructured":"Zhang C, Ling X, Guo Y, Yuan C, Cheng H, Ye X, et al. Evaluation of COC183B2 antibody targeting ovarian cancer by near-infrared fluorescence imaging. Chin J Cancer Res. 2019;31:673\u201385.","journal-title":"Chin J Cancer Res"},{"key":"1547_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13058-015-0538-7","volume":"17","author":"HA Azim Jr","year":"2015","unstructured":"Azim HA Jr., Peccatori FA, Brohee S, Branstetter D, Loi S, Viale G, et al. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res. 2015;17:24.","journal-title":"Breast Cancer Res"},{"key":"1547_CR24","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.7150\/thno.24252","volume":"8","author":"A El-Sayed","year":"2018","unstructured":"El-Sayed A, Bernhard W, Barreto K, Gonzalez C, Hill W, Pastushok L, et al. Evaluation of antibody fragment properties for near-infrared fluorescence imaging of HER3-positive cancer xenografts. Theranostics. 2018;8:4856\u201369.","journal-title":"Theranostics"},{"key":"1547_CR25","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.7150\/thno.9899","volume":"4","author":"C Chi","year":"2014","unstructured":"Chi C, Du Y, Ye J, Kou D, Qiu J, Wang J, et al. Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology. Theranostics. 2014;4:1072\u201384.","journal-title":"Theranostics"},{"key":"1547_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.21037\/atm-22-6455","volume":"11","author":"S Kashiwagi","year":"2023","unstructured":"Kashiwagi S, Choi HS. Ovarian cancer-targeted near-infrared fluorophores for fluorescence-guided surgery. Ann Transl Med. 2023;11:274.","journal-title":"Ann Transl Med"},{"key":"1547_CR27","doi-asserted-by":"crossref","unstructured":"Wang Z, Yang F, Zhao X, Mi J, Sun L, Kang N et al. Outcome of near-infrared fluorescence-navigated pulmonary metastasectomy for hepatocellular carcinoma. Eur J Cardiothorac Surg. 2022;62(5):ezac270.","DOI":"10.1093\/ejcts\/ezac270"},{"key":"1547_CR28","doi-asserted-by":"publisher","first-page":"e0129766","DOI":"10.1371\/journal.pone.0129766","volume":"10","author":"QR Tummers","year":"2015","unstructured":"Tummers QR, Hoogstins CE, Peters AA, de Kroon CD, Trimbos JB, van de Velde CJ, et al. The value of Intraoperative Near-Infrared fluorescence imaging based on enhanced permeability and Retention of Indocyanine Green: feasibility and false-positives in Ovarian Cancer. PLoS ONE. 2015;10:e0129766.","journal-title":"PLoS ONE"},{"key":"1547_CR29","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1021\/acs.molpharmaceut.0c00437","volume":"17","author":"K Fung","year":"2020","unstructured":"Fung K, Sharma SK, Keinanen O, Roche KL, Lewis JS, Zeglis BM. A molecularly targeted intraoperative Near-Infrared fluorescence imaging Agent for High-Grade Serous Ovarian Cancer. Mol Pharm. 2020;17:3140\u20137.","journal-title":"Mol Pharm"},{"key":"1547_CR30","doi-asserted-by":"crossref","unstructured":"Kleinmanns K, Fosse V, Bjorge L, McCormack E. The emerging role of CD24 in Cancer Theranostics-A Novel Target for fluorescence image-guided surgery in Ovarian Cancer and Beyond. J Pers Med. 2020;10.","DOI":"10.3390\/jpm10040255"},{"key":"1547_CR31","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1158\/1078-0432.CCR-14-3284","volume":"21","author":"EL Rosenthal","year":"2015","unstructured":"Rosenthal EL, Warram JM, de Boer E, Chung TK, Korb ML, Brandwein-Gensler M, et al. Safety and Tumor specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer. Clin Cancer Res. 2015;21:3658\u201366.","journal-title":"Clin Cancer Res"},{"key":"1547_CR32","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1245\/s10434-012-2435-y","volume":"19","author":"CH Heath","year":"2012","unstructured":"Heath CH, Deep NL, Sweeny L, Zinn KR, Rosenthal EL. Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model. Ann Surg Oncol. 2012;19:3879\u201387.","journal-title":"Ann Surg Oncol"},{"key":"1547_CR33","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.7150\/thno.24487","volume":"8","author":"RW Gao","year":"2018","unstructured":"Gao RW, Teraphongphom N, de Boer E, van den Berg NS, Divi V, Kaplan MJ, et al. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers. Theranostics. 2018;8:2488\u201395.","journal-title":"Theranostics"},{"key":"1547_CR34","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00259-022-05975-7","volume":"50","author":"C Li","year":"2023","unstructured":"Li C, Mi J, Wang Y, Zhang Z, Guo X, Zhou J, et al. New and effective EGFR-targeted fluorescence imaging technology for intraoperative rapid determination of lung cancer in freshly isolated tissue. Eur J Nucl Med Mol Imaging. 2023;50:494\u2013507.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1547_CR35","doi-asserted-by":"publisher","first-page":"9589820","DOI":"10.1155\/2022\/9589820","volume":"2022","author":"A Amini","year":"2022","unstructured":"Amini A, Safdari Y, Tash Shamsabadi F. Near-Infrared fluorescence imaging of EGFR-Overexpressing tumors in the mouse xenograft model using scFv-IRDye800CW and Cetuximab-IRDye800CW. Mol Imaging. 2022;2022:9589820.","journal-title":"Mol Imaging"},{"key":"1547_CR36","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1021\/acs.molpharmaceut.2c00115","volume":"19","author":"L Wang","year":"2022","unstructured":"Wang L, Liang M, Xiao Y, Chen J, Mei C, Lin Y, et al. NIR-II Navigation with an EGFR-Targeted probe improves Imaging Resolution and Sensitivity of detecting micrometastases in esophageal squamous cell carcinoma xenograft models. Mol Pharm. 2022;19:3563\u201375.","journal-title":"Mol Pharm"},{"key":"1547_CR37","doi-asserted-by":"crossref","unstructured":"Zhu CN, Chen G, Tian ZQ, Wang W, Zhong WQ, Li Z et al. Near-Infrared fluorescent ag(2) Se-Cetuximab Nanoprobes for targeted imaging and therapy of Cancer. Small. 2017;13.","DOI":"10.1002\/smll.201602309"},{"key":"1547_CR38","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1016\/j.biomaterials.2013.03.061","volume":"34","author":"T Sadhukha","year":"2013","unstructured":"Sadhukha T, Wiedmann TS, Panyam J. Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. Biomaterials. 2013;34:5163\u201371.","journal-title":"Biomaterials"},{"key":"1547_CR39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nmat4476","volume":"15","author":"AL Antaris","year":"2016","unstructured":"Antaris AL, Chen H, Cheng K, Sun Y, Hong G, Qu C, et al. A small-molecule dye for NIR-II imaging. Nat Mater. 2016;15:235\u201342.","journal-title":"Nat Mater"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-024-01547-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-024-01547-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-024-01547-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T13:04:36Z","timestamp":1731589476000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-024-01547-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1547"],"URL":"https:\/\/doi.org\/10.1186\/s13048-024-01547-5","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"assertion":[{"value":"22 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This experiment was approved by the Medical Ethics Committee of Peking University People\u2019s Hospital (No.2016PHC078), and all patients signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}